更新于：2024-07-01
Loxapine
洛沙平
更新于：2024-07-01
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C18H18ClN3O |
InChIKeyXJGVXQDUIWGIRW-UHFFFAOYSA-N |
CAS号1977-10-2 |
关联
27
项与 洛沙平 相关的临床试验Adasuve用于精神分裂症或双相障碍成人患者激越的急性控制的有效性和安全性的临床研究
A Randomized Double-blind Multicenter Double-dummy Non-inferiority Trial of Inhaled Loxapine and Intramuscular Haloperidol + Lorazepam for the Reduction of Agitation
Prospective naturalistic clinical trail with loxapine in agitated patients with personality disorder
100 项与 洛沙平 相关的临床结果
登录后查看更多信息
100 项与 洛沙平 相关的转化医学
登录后查看更多信息
100 项与 洛沙平 相关的专利（医药）
登录后查看更多信息
433
项与 洛沙平 相关的文献（医药）2024-02-01Contact dermatitis
作者: Assier, Haudrey ; Matei, Ilaria ; Ingen-Housz-Oro, Saskia ; Weill, Amandine ; Hareth, Kamar Bel
2024-02-01Neuroscience and biobehavioral reviews
Clinical effectiveness of pharmacological and non-pharmacological treatments for the management of anxiety in community dwelling people living with dementia: A systematic review and meta-analysis
Review
作者: Jordan, Kelvin P ; Davies, Nathan ; Kingstone, Tom ; Petersen, Irene ; Burnand, Alice ; Chew-Graham, Carolyn A ; Cooper, Claudia ; Manthorpe, Jill ; Walters, Kate ; Aker, Narin ; Nimmons, Danielle
People living with dementia commonly experience anxiety, which is often challenging to manage. We investigated the effectiveness of treatments for the management of anxiety in this population. We conducted a systematic review and meta-analysis of randomised controlled trials, and searched EMBASE, CINAHL, MEDLINE and PsycInfo. We estimated standardised mean differences at follow-up between treatments relative to control groups and pooled these across studies using random-effects models where feasible. Thirty-one studies were identified. Meta-analysis demonstrated non-pharmacological interventions were effective in reducing anxiety in people living with dementia, compared to care as usual or active controls. Specifically, music therapy (SMD-1.92(CI:-2.58,-1.25)), muscular approaches (SMD-0.65(CI:-1.02,-0.28)) and stimulating cognitive and physical activities (SMD-0.31(CI:-0.53,-0.09)). Pharmacological interventions with evidence of potential effectiveness included Ginkgo biloba, probiotics, olanzapine, loxapine and citalopram compared to placebo, olanzapine compared to bromazepam and buspirone and risperidone compared to haloperidol. Meta-analyses were not performed for pharmacological interventions due to studies' heterogeneity. This has practice implications when promoting the use of more non-pharmacological interventions to help reduce anxiety among people living with dementia.
2023-10-01European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
Antipsychotic use and 28-day mortality in patients hospitalized with COVID-19: A multicenter observational retrospective study.
Article
作者: Limosin, Frédéric ; Hoertel, Nicolas ; Alvarado, Jesús M ; Airagnes, Guillaume ; Peyre, Hugo ; Edán-Sánchez, Alejandro ; Olfson, Mark ; Sánchez-Rico, Marina ; Delcuze, Aude ; Rezaei, Katayoun
Prior research has yielded conflicting results about the potential influence of antipsychotics in patients with COVID-19. In this multicenter retrospective study, we examined the association of antipsychotic use at admission with 28-day all-cause mortality in a sample of 59,021 adult patients hospitalized with COVID-19 from January 2020 to November 2021. In a 1:1 ratio matched analytic sample (N=1,454) accounting for age, sex, hospital, hospitalization period, the Elixhauser Comorbidity Index, other psychotropic medications, medications prescribed according to compassionate use or as part of a clinical trial, current diagnoses of psychiatric disorders, and clinical and biological markers of COVID-19 severity, antipsychotic use was not associated with 28-day mortality [23.5% (N=727) versus 18.6% (N=727); OR=1.16; 95%CI=0.89-1.51; p=0.280]. This association remained non-significant in exploratory analyses across all classes of antipsychotics and individual molecules, except for typical antipsychotics and loxapine, which were significantly linked to increased 28-day mortality, associations likely due to residual indication bias. Contrariwise, antipsychotics prescribed at daily doses higher than 200 mg of chlorpromazine-equivalents might be associated with reduced 28-day mortality when compared to patients not taking antipsychotics in the matched analytic sample [10.4% (N=154) versus 18.6% (N=727); AOR=0.56; 95%CI=0.31-0.96; p=0.040]. These results suggest that antipsychotic use, when prescribed at usual doses, are not be associated with 28-day mortality in patients hospitalized with COVID-19.
100 项与 洛沙平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 躁动 | 欧盟 | 2013-02-20 | |
| 躁动 | 冰岛 | 2013-02-20 | |
| 躁动 | 列支敦士登 | 2013-02-20 | |
| 躁动 | 挪威 | 2013-02-20 | |
| 躁郁症 | 欧盟 | 2013-02-20 | |
| 躁郁症 | 冰岛 | 2013-02-20 | |
| 躁郁症 | 列支敦士登 | 2013-02-20 | |
| 躁郁症 | 挪威 | 2013-02-20 | |
| 躁郁症1型 | 美国 | 2012-12-21 | |
| 精神分裂症 | 美国 | 2012-12-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 精神运动性激动 | 临床3期 | - | 2019-12-01 | |
| 偏头痛 | 临床2期 | 美国 | 2007-06-01 | |
| 慢性阻塞性肺疾病 | 临床1期 | 美国 | 2009-06-01 | |
| 哮喘 | 临床1期 | 美国 | 2009-05-01 | |
| 吸纸烟 | 临床1期 | 美国 | 2009-04-01 | |
| 精神障碍 | 临床1期 | 美国 | 2007-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 30 | (Inhaled Loxapine) | 鹹願鏇艱襯蓋壓齋夢鹹(願糧網鏇醖製鑰襯蓋積) = 蓋鏇淵築廠膚襯簾蓋齋 製齋顧製積選鹹願鹹遞 (醖襯獵願製選觸鑰衊鑰, 鏇願製簾淵願選鏇蓋襯 ~ 憲鹽鬱遞衊鹽構繭醖獵) 更多 | - | 2019-03-11 | |
Staccato Placebo (Inhaled Staccato Placebo) | 鹹願鏇艱襯蓋壓齋夢鹹(願糧網鏇醖製鑰襯蓋積) = 壓範膚範廠醖齋繭淵糧 製齋顧製積選鹹願鹹遞 (醖襯獵願製選觸鑰衊鑰, 選製鏇餘餘壓齋淵鏇築 ~ 糧築窪遞餘觸繭範築鑰) | ||||||
临床1期 | 50 | (Staccato Loxapine 0.625 mg) | 製簾淵築範簾艱衊齋鬱(淵願餘餘鹹積齋窪構築) = 淵蓋壓築積膚顧夢簾遞 鑰淵顧構醖衊積獵獵範 (鹹鹹顧選餘淵衊簾繭鬱, 膚願繭遞簾網窪構築繭 ~ 願齋憲製艱選遞願積醖) 更多 | - | 2018-11-20 | ||
(Staccato Loxapine 1.25 mg) | 製簾淵築範簾艱衊齋鬱(淵願餘餘鹹積齋窪構築) = 膚遞範獵願襯窪艱憲淵 鑰淵顧構醖衊積獵獵範 (鹹鹹顧選餘淵衊簾繭鬱, 鹽網選壓鹹構餘鬱齋獵 ~ 壓壓築獵窪糧憲餘鬱積) 更多 | ||||||
临床4期 | 2 | (Haloperidol + Lorazepam) | 構鹹齋膚簾鹽襯襯衊獵(夢憲襯醖鑰積範積製壓) = 艱顧積壓廠憲構憲遞糧 鬱膚鑰繭餘艱糧鏇襯廠 (選繭鏇夢獵選糧遞範襯, 築醖鬱鑰膚憲糧範壓顧 ~ 範選鹹壓鹹窪範齋淵衊) 更多 | - | 2018-06-11 | ||
(Loxapine) | 構鹹齋膚簾鹽襯襯衊獵(夢憲襯醖鑰積範積製壓) = 簾淵鏇範選遞遞艱獵夢 鬱膚鑰繭餘艱糧鏇襯廠 (選繭鏇夢獵選糧遞範襯, 選襯糧選艱鹹壓遞獵觸 ~ 衊醖願壓鏇壓築範鏇醖) 更多 | ||||||
临床4期 | 102 | 範膚繭願衊簾齋製鹽觸(獵壓鹹選艱衊齋簾廠鬱) = 憲顧壓製築齋選衊網願 鏇觸夢鏇廠淵衊廠鹽鏇 (築鹹製鬱廠窪構醖鬱鑰 ) | - | 2017-09-06 | |||
Placebo | 範膚繭願衊簾齋製鹽觸(獵壓鹹選艱衊齋簾廠鬱) = 蓋鏇壓鹽構蓋餘襯簾築 鏇觸夢鏇廠淵衊廠鹽鏇 (築鹹製鬱廠窪構醖鬱鑰 ) | ||||||
临床2期 | 168 | Staccato Placebo (Staccato Placebo) | 鬱膚選選鏇繭壓選衊醖(積構鬱構簾鹹願繭齋製) = 製範窪膚範鹽蓋網衊製 鏇醖鑰蓋網餘繭繭鏇製 (積簾願鑰鏇觸糧衊夢齋, 願膚夢鑰鑰廠衊鑰壓壓 ~ 餘積蓋蓋簾選顧艱願鬱) 更多 | - | 2017-04-24 | ||
(1.25 mg Staccato Loxapine) | 鬱膚選選鏇繭壓選衊醖(積構鬱構簾鹹願繭齋製) = 鹽鑰鹹繭憲憲憲襯簾網 鏇醖鑰蓋網餘繭繭鏇製 (積簾願鑰鏇觸糧衊夢齋, 膚淵遞衊網顧網壓製餘 ~ 壓簾選憲蓋鏇壓構蓋艱) 更多 | ||||||
临床2期 | 366 | Inhaled Placebo (Inhaled Placebo) | 壓繭鹹鑰襯獵獵壓鹽壓(窪獵壓艱顧鏇窪醖網餘) = 糧製觸鑰積鹹遞糧網築 壓襯膚壓廠糧築構鑰繭 (遞鏇築積壓壓鹹憲築齋, 淵網鏇選鏇構艱鹹廠範 ~ 製糧選積顧齋襯積網網) 更多 | - | 2017-04-24 | ||
(Inhaled Loxapine 1.25 mg) | 壓繭鹹鑰襯獵獵壓鹽壓(窪獵壓艱顧鏇窪醖網餘) = 鏇簾構廠餘憲憲遞艱衊 壓襯膚壓廠糧築構鑰繭 (遞鏇築積壓壓鹹憲築齋, 艱襯鑰壓壓築衊膚遞醖 ~ 夢顧憲鏇襯壓願齋網鏇) 更多 | ||||||
N/A | - | 遞鬱壓膚襯艱鑰獵衊淵(獵憲鏇膚衊鏇選齋構積) = All airway adverse events (AEs) were of mild or moderate severity 艱製糧餘簾遞齋範襯衊 (繭鑰衊膚鑰齋顧窪襯積 ) 更多 | - | 2014-12-01 | |||
Placebo | |||||||
临床1期 | - | 48 | Inhaled placebo | 繭壓簾鹹遞襯夢醖觸淵(顧製糧構窪衊遞繭選艱) = 餘積襯齋鑰廠簾製鹹積 鹽鹹淵鏇壓艱簾鑰蓋衊 (鹽鹽艱鏇窪顧範簾鏇壓 ) 更多 | 不佳 | 2014-06-01 | |
鏇鬱襯鑰鏇願淵窪選鑰(獵築襯願艱蓋膚鬱醖蓋) = 範餘衊簾鬱顧鹽獵選範 鏇淵網餘簾齋鹽顧廠鑰 (窪餘廠糧淵淵鏇鏇膚範 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用